ArticleNature metabolism2023
Upregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice.
Article in Nature metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Efficacy and mechanisms ofFrontiers in pharmacology · 2026Pooled it
- Integrating WGCNA and machine learning to identify and validate key biomarkers in MASLD.BMC gastroenterology · 2026Article
- [WD40 repeat-containing protein 6 aggravates diabetic kidney disease by promoting lipid accumulation in kidney].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Article
- Article
- Mup3 ameliorates the dysregulation of glucose and lipid metabolism in MAFLD.Acta pharmacologica Sinica · 2026Article
- Physical exercise in liver diseases.Hepatology (Baltimore, Md.) · 2026Review
- Insulin resistance: mechanisms and therapeutic interventions.Molecular biomedicine · 2026Review
- Multi-site microbiota crosstalk in the postmenopausal: from dysbiosis mechanisms to precision interventions.Frontiers in microbiology · 2026Review
- Acetylshikonin mitigates diet-induced MASLD by targeting PPARγ-mediated metabolic dysfunction.Frontiers in pharmacology · 2026Article
- Peripheral organ crosstalk in the regulation of ovarian endocrine function and reproductive homeostasis.Life medicine · 2025Review
- Causal pathways of plasma metabolites: unveiling metabolic associations in liver diseases.Nutrition & metabolism · 2025Article
- Bibliometric visualization of hepatocellular carcinoma and metabolic syndrome research: trends and emerging areas.Discover oncology · 2025Article
- WDR36 Regulates Trophectoderm Differentiation During Human Preimplantation Embryonic Development Through Glycolytic Metabolism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Mapping the Intellectual Landscape: A 20-Year Bibliometric Analysis of Mechanisms in Metabolic Dysfunction-Associated Steatotic Liver Disease.Hepatic medicine : evidence and research · 2025Article
- Unveiling the endocrine connections of NAFLD: evidence from a comprehensive mendelian randomization study.Biomedical engineering letters · 2025Article
- Dietary isobutyric acid supplementation improves intestinal mucosal barrier function and meat quality by regulating cecal microbiota and serum metabolites in weaned piglets.Frontiers in veterinary science · 2025Article
- De novo lipid synthesis in cardiovascular tissue and disease.Atherosclerosis · 2025Review
- High mobility group A1 (HMGA1) promotes the tumorigenesis of colorectal cancer by increasing lipid synthesis.Nature communications · 2024Article
- Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy.Signal transduction and targeted therapy · 2024 · on this mapReview
- Identification of Amino Acids in Trm734 Required for 2'-ACS omega · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Under normal conditions, insulin promotes hepatic de novo lipogenesis (DNL). However, during insulin resistance (IR), when insulin signalling is blunted and accompanied by hyperinsulinaemia, the promotion of hepatic DNL continues unabated and hepatic steatosis increases. Here, we show that WD40 repeat-containing protein 6 (WDR6) promotes hepatic DNL during IR. Mechanistically, WDR6 interacts with the beta-type catalytic subunit of serine/threonine-protein phosphatase 1 (PPP1CB) to facilitate PPP1CB dephosphorylation at Thr316, which subsequently enhances fatty acid synthases transcription through DNA-dependent protein kinase and upstream stimulatory factor 1. Using molecular dynamics simulation analysis, we find a small natural compound, XLIX, that inhibits the interaction of WDR6 with PPP1CB, thus reducing DNL in IR states. Together, these results reveal WDR6 as a promising target for the treatment of hepatic steatosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.